Shiraishi Makoto, Narushima Mitsunaga, Banda Chihena Hansini, Mitsui Kohei, Danno Kanako, Ishiura Ryohei, Kurita Masakazu, Yuzuriha Shunsuke, Okazaki Mutsumi
Department of Plastic and Reconstructive Surgery, Graduate School of Medicine, Mie University, Tsu, Mie, Japan.
Department of Plastic and Reconstructive Surgery, The University of Tokyo Hospital, Tokyo, Japan.
Ann Vasc Dis. 2023 Jun 25;16(2):101-107. doi: 10.3400/avd.oa.22-00126.
Concerns among susceptible individuals, especially those with vascular malformations, have been raised by reports of thromboembolism following the administration of the SARS-CoV-2 vaccination against coronavirus disease 2019 (COVID-19). This study's goal was to assess any negative side effects that patients with vascular malformations who received the SARS-CoV-2 vaccine reported after receiving it. Through the three patient groups for vascular malformations in Japan in November 2021, a questionnaire was distributed to patients with vascular malformations who were 12 years of age or older. Multiple regression analysis was used to find relevant variables. A total of 128 patients responded, representing a response rate of 58.8%. Ninety-six participants (75.0%) had received at least one dose of SARS-CoV-2 vaccine. In total, 84 (87.5%) and 84 (89.4%) subjects experienced at least 1 general adverse response following dose 1 and dose 2, respectively. Adverse reactions related to vascular malformations were reported by 15 participants (16.0%) after the 1st dose and 17 (17.7%) after the 2nd dose. Notably, no case of thromboembolism following vaccination was reported. The rate of vaccine-related adverse reactions in patients with vascular malformations is not different from that reported in the general population. There is no report of life-threatening responses in the research population.
针对2019冠状病毒病（COVID-19）的严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）疫苗接种后出现血栓栓塞的报道，引发了易感人群尤其是患有血管畸形者的担忧。本研究的目的是评估接种SARS-CoV-2疫苗的血管畸形患者在接种后报告的任何负面副作用。2021年11月，通过日本的三个血管畸形患者群体，向12岁及以上的血管畸形患者发放了问卷。采用多元回归分析来寻找相关变量。共有128名患者做出回应，回应率为58.8%。96名参与者（75.0%）至少接种了一剂SARS-CoV-2疫苗。总共84名（87.5%）和84名（89.4%）受试者在第1剂和第2剂接种后分别经历了至少1次一般不良反应。15名参与者（16.0%）在第1剂接种后报告了与血管畸形相关的不良反应，17名（17.7%）在第2剂接种后报告了相关不良反应。值得注意的是，未报告接种后出现血栓栓塞的病例。血管畸形患者中与疫苗相关的不良反应发生率与普通人群报告的发生率没有差异。研究人群中没有危及生命反应的报告。
